Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony W Tolcher

Showing results (31-40 of 123) with videos related to

Pageof 13
Sort By:
BMC Dermatology|April 21, 2006
Case report and summary of literature: giant perineal keloids treated with post-excisional radiotherapyKristin Jones, Clifton D Fuller, Join Y Luh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 22, 2009
Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect studyAlejandro D Ricart, John Sarantopoulos, Emiliano Calvo, et al.
Cancer Chemotherapy and Pharmacology|May 23, 2014
Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumorsMonica Mita, Michael Gordon, Lee Rosen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2002
A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancerAnthony W Tolcher, Leonard Reyno, Peter M Venner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2008
Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignanciesLouis M Weiner, Arie S Belldegrun, Jeffrey Crawford, et al.
Cancer|January 7, 2010
A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancerStacy L Moulder, Frankie A Holmes, Anthony W Tolcher, et al.
Cancer Chemotherapy and Pharmacology|October 1, 2015
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumorsAnthony W Tolcher, Patricia LoRusso, Jennifer Arzt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2024
Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid TumorsAnthony W Tolcher, Joshua D Brody, Nishanthan Rajakumaraswamy, et al.
Cancer Chemotherapy and Pharmacology|April 2, 2013
Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancerAmita Patnaik, Kyriakos P Papadopoulos, Anthony W Tolcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2024
First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid TumorsTimothy A Yap, Anthony W Tolcher, Ruth Plummer, et al.
Pageof 13

Showing results (31-40 of 123) with videos related to

Sort By:
Pageof 13
BMC Dermatology|April 21, 2006
Case report and summary of literature: giant perineal keloids treated with post-excisional radiotherapyKristin Jones, Clifton D Fuller, Join Y Luh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 22, 2009
Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect studyAlejandro D Ricart, John Sarantopoulos, Emiliano Calvo, et al.
Cancer Chemotherapy and Pharmacology|May 23, 2014
Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumorsMonica Mita, Michael Gordon, Lee Rosen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2002
A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancerAnthony W Tolcher, Leonard Reyno, Peter M Venner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2008
Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignanciesLouis M Weiner, Arie S Belldegrun, Jeffrey Crawford, et al.
Cancer|January 7, 2010
A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancerStacy L Moulder, Frankie A Holmes, Anthony W Tolcher, et al.
Cancer Chemotherapy and Pharmacology|October 1, 2015
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumorsAnthony W Tolcher, Patricia LoRusso, Jennifer Arzt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2024
Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid TumorsAnthony W Tolcher, Joshua D Brody, Nishanthan Rajakumaraswamy, et al.
Cancer Chemotherapy and Pharmacology|April 2, 2013
Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancerAmita Patnaik, Kyriakos P Papadopoulos, Anthony W Tolcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2024
First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid TumorsTimothy A Yap, Anthony W Tolcher, Ruth Plummer, et al.
Pageof 13